COMMUNIQUÉS West-GlobeNewswire

Libtayo® (cemiplimab-rwlc) Approved in the U.S. as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation
08/10/2025
Approval based on pivotal Phase 3 C-POST trial showing Libtayo significantly reduced the risk of disease recurrence or death by 68% compared to placebo (hazard ratio: 0.32; 95% confidence interval: 0.20-0.51; p<0. [...]
Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering
08/10/2025
SAN FRANCISCO and BOSTON, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles [...]
Ascendis Submits Marketing Authorisation Application to the European Medicines Agency for TransCon® CNP for Treatment of Children with Achondroplasia
08/10/2025
COPENHAGEN, Denmark, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for TransCon [...]
Medicare Now Reimbursing for EnteroTrack’s Esophageal String Test®, Expanding Access to Patients with Eosinophilic Esophagitis
08/10/2025
AURORA, Colo., Oct. 08, 2025 (GLOBE NEWSWIRE) -- EnteroTrack LLC announced that the Centers for Medicare & Medicaid Services (CMS) is paying for the company’s Esophageal String Test ® (EST), marking a major [...]
Channel Medsystems Appoints Healthcare Executive Skip Baldino to Board of Directors
08/10/2025
BERKELEY, Calif., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Channel Medsystems, Inc., a privately held company dedicated to advancing women’s health with innovative solutions, announced today the appointment of Skip Baldino to [...]
Serina Therapeutics Launches Enhanced Corporate Communications Platform to Strengthen Engagement with Patients, Clinicians, and Investors
08/10/2025
HUNTSVILLE, AL., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform ™ drug optimization technology [...]
Tessera Therapeutics Awarded up to $41.3 Million from ARPA-H to Advance In Vivo CAR-T Therapies
08/10/2025
Award will support development of a single dose in vivo chimeric antigen receptor T cell (CAR-T) therapy to retrain immune cells directly within the body to fight cancer and autoimmune diseases using Tessera’s Gene [...]
Protext Mobility, Inc. (OTC: TXTM) Announces New Member of Its Advisory Board
08/10/2025
WILMINGTON, Del., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Protext Mobility, Inc. (OTC: TXTM), an emerging innovator in the biotechnology and alternative wellness sector, today announced the first members of its Advisory Board [...]
Unyte Health Celebrates 10 Years as the Leader in Nervous System Regulation and Sound-Based Listening Therapies
08/10/2025
DENVER, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Ten years, 10,000 trained providers, and over 100,000 lives transformed: Unyte Health celebrates a decade of pioneering sound-based interventions that bring the science of [...]
Turn Therapeutics to Commence Trading Today on Nasdaq
08/10/2025
Founder & CEO, Bradley Burnam, to Ring NASDAQ “Closing Bell” at 4:00 PM ET WESTLAKE VILLAGE, Calif., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics (“Turn” or the “Company”), a clinical-stage biotechnology [...]
Ashvattha Therapeutics to Present Phase 2 DME and nAMD Data at Innovate Retina
08/10/2025
Migaldendranib (MGB), a subcutaneous nanomedicine, represents potential paradigm shift from frequent intravitreal injections REDWOOD CITY, Calif., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), [...]
ARS Pharmaceuticals Receives Favorable Decision from European Patent Office on Patent Related to neffy® (epinephrine nasal spray)
08/10/2025
SAN DIEGO, Oct. 08, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a commercial-stage biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect [...]
Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer
08/10/2025
Fast Track Designation underscores the promise of Werewolf’s INDUKINE™ platform WATERTOWN, Mass., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), pioneering [...]
MAPS and HoloMind Institute Host International MDMA-Assisted Therapy Training in Poland
08/10/2025
Training marks Poland's first International Psychedelic Therapy Training Program, expanding MAPS' global education initiative Program demonstrates MAPS' commitment to expanding global access to psychedelic healing [...]
Izotropic Marks Breast Cancer Awareness Month by Highlighting Gaps in Care and the Need for IzoView Breast CT
08/10/2025
VANCOUVER, British Columbia, and SACRAMENTO, Calif., Oct. 08, 2025 (GLOBE NEWSWIRE) -- via IBN – Izotropic Corporation (CSE: IZO ) (OTCQB: IZOZF ) (FSE: 1R3 ) (“ Izotropic ”, or the “ Company ”), a medical device [...]
Vaxart to Showcase its Norovirus and COVID-19 Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2025
08/10/2025
SOUTH SAN FRANCISCO, Calif., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on [...]
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08/10/2025
MIAMI, Oct. 08, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard ® Prime carotid stent system for the prevention of stroke, today announced that the [...]
Starton Therapeutics to Share Innovative Lenalidomide Delivery Technology on Labroots Webinar Sponsored by Primetech Corporation
08/10/2025
PARAMUS, N.J., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton”), a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary continuous delivery technologies, [...]
Nasus Pharma Announces Expanded Agreement to Support Development and Commercialization of NS002 Intranasal Epinephrine Program
08/10/2025
Strategic collaboration with leading global manufacturer of drug delivery systems strengthens NS002's clinical and commercial roadmap with end-to-end development support and manufacturing infrastructure TEL AVIV, Oct. [...]

Pages